Cargando…
Worsening of asthma control after COVID-19
BACKGROUND: SARS-CoV-2 enters lung cells via angiotensin-converting enzyme 2 (ACE2) receptor. Several studies suggest that interleukin-13, an important cytokine involved in T2 inflammation, reduces ACE2 expression, and therefore, asthma would not be a significant risk factor for the development of s...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524244/ https://www.ncbi.nlm.nih.gov/pubmed/36186769 http://dx.doi.org/10.3389/fmed.2022.882665 |
_version_ | 1784800464199483392 |
---|---|
author | Agondi, Rosana Câmara Menechino, Natália Marinho, Ana Karolina Barreto Berselli Kalil, Jorge Giavina-Bianchi, Pedro |
author_facet | Agondi, Rosana Câmara Menechino, Natália Marinho, Ana Karolina Barreto Berselli Kalil, Jorge Giavina-Bianchi, Pedro |
author_sort | Agondi, Rosana Câmara |
collection | PubMed |
description | BACKGROUND: SARS-CoV-2 enters lung cells via angiotensin-converting enzyme 2 (ACE2) receptor. Several studies suggest that interleukin-13, an important cytokine involved in T2 inflammation, reduces ACE2 expression, and therefore, asthma would not be a significant risk factor for the development of severe COVID-19. However, several asthma-related risk factors should be valued during the concurrent occurrence of asthma and COVID-19. The purpose of this study was to compare the evolution of asthma in patients who had COVID-19 with those who did not have the disease. METHODS: This was an observational and retrospective study involving asthmatic patients followed up at a tertiary center. Patients were assessed for severity of asthma, atopy, comorbidities, and COVID-19. Worsening of asthma was considered when, during the period of Sept 2020 to Oct 2021, patients referred an increasing of asthma symptoms and a need to increment their maintenance therapy. RESULTS: This study included 208 asthmatic patients, the mean age was 52.75 years, 79.81% were atopic asthmatics, and 59 (28.37%) had laboratory-confirmed coronavirus disease. Of all patients infected with the SARS-CoV-2, eleven (18.64%) needed hospitalization and required oxygen supply with an O2 mask. Comparing the worsening of asthma between patients who had COVID-19 and those who had not the disease, there was a statistically significant difference, 33.90 vs. 11.41%, respectively (p < 0.001). There was no statistical significance regarding asthma comorbidities. CONCLUSION: This study assessed a group of asthmatic patients that had COVID-19, and that although the respiratory symptoms related to COVID-19 were mild to moderate, a subgroup of these asthmatic patients evolved with a chronic worsening of their asthma requiring an increment in asthma medication to control the disease. |
format | Online Article Text |
id | pubmed-9524244 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95242442022-10-01 Worsening of asthma control after COVID-19 Agondi, Rosana Câmara Menechino, Natália Marinho, Ana Karolina Barreto Berselli Kalil, Jorge Giavina-Bianchi, Pedro Front Med (Lausanne) Medicine BACKGROUND: SARS-CoV-2 enters lung cells via angiotensin-converting enzyme 2 (ACE2) receptor. Several studies suggest that interleukin-13, an important cytokine involved in T2 inflammation, reduces ACE2 expression, and therefore, asthma would not be a significant risk factor for the development of severe COVID-19. However, several asthma-related risk factors should be valued during the concurrent occurrence of asthma and COVID-19. The purpose of this study was to compare the evolution of asthma in patients who had COVID-19 with those who did not have the disease. METHODS: This was an observational and retrospective study involving asthmatic patients followed up at a tertiary center. Patients were assessed for severity of asthma, atopy, comorbidities, and COVID-19. Worsening of asthma was considered when, during the period of Sept 2020 to Oct 2021, patients referred an increasing of asthma symptoms and a need to increment their maintenance therapy. RESULTS: This study included 208 asthmatic patients, the mean age was 52.75 years, 79.81% were atopic asthmatics, and 59 (28.37%) had laboratory-confirmed coronavirus disease. Of all patients infected with the SARS-CoV-2, eleven (18.64%) needed hospitalization and required oxygen supply with an O2 mask. Comparing the worsening of asthma between patients who had COVID-19 and those who had not the disease, there was a statistically significant difference, 33.90 vs. 11.41%, respectively (p < 0.001). There was no statistical significance regarding asthma comorbidities. CONCLUSION: This study assessed a group of asthmatic patients that had COVID-19, and that although the respiratory symptoms related to COVID-19 were mild to moderate, a subgroup of these asthmatic patients evolved with a chronic worsening of their asthma requiring an increment in asthma medication to control the disease. Frontiers Media S.A. 2022-09-14 /pmc/articles/PMC9524244/ /pubmed/36186769 http://dx.doi.org/10.3389/fmed.2022.882665 Text en Copyright © 2022 Agondi, Menechino, Marinho, Kalil and Giavina-Bianchi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Agondi, Rosana Câmara Menechino, Natália Marinho, Ana Karolina Barreto Berselli Kalil, Jorge Giavina-Bianchi, Pedro Worsening of asthma control after COVID-19 |
title | Worsening of asthma control after COVID-19 |
title_full | Worsening of asthma control after COVID-19 |
title_fullStr | Worsening of asthma control after COVID-19 |
title_full_unstemmed | Worsening of asthma control after COVID-19 |
title_short | Worsening of asthma control after COVID-19 |
title_sort | worsening of asthma control after covid-19 |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524244/ https://www.ncbi.nlm.nih.gov/pubmed/36186769 http://dx.doi.org/10.3389/fmed.2022.882665 |
work_keys_str_mv | AT agondirosanacamara worseningofasthmacontrolaftercovid19 AT menechinonatalia worseningofasthmacontrolaftercovid19 AT marinhoanakarolinabarretoberselli worseningofasthmacontrolaftercovid19 AT kaliljorge worseningofasthmacontrolaftercovid19 AT giavinabianchipedro worseningofasthmacontrolaftercovid19 |